학술논문

Development of an inactivated 3Cpro-3ABC (mu3ABC) ELISA to differentiate cattle infected with foot and mouth disease virus from vaccinated cattle
Document Type
Article
Source
Journal of Virological Methods. Mar2013, Vol. 188 Issue 1/2, p161-167. 7p.
Subject
*ENZYME-linked immunosorbent assay
*FOOT & mouth disease
*CATTLE vaccination
*COMMUNICABLE diseases
*ENDEMIC animals
*IMMUNE response
*GENE expression
Language
ISSN
0166-0934
Abstract
Abstract: Foot and mouth disease, a highly contagious disease of cloven-hoofed animals, is still endemic in Asia, Africa, and a few countries in South America. Subclinical and persistent infections usually occur in vaccinated cattle exposed to FMDV. Successful control and eradication measures need a diagnostic assay that can distinguish between immune responses to infection and vaccination. The non-structural 3ABC ELISA is the most reliable differential diagnostic assay. However, expression of the native 3ABC gene in insect cells yielded truncated versions of the proteins; thus, a monoclonal antibody to capture digested proteins is needed to develop the assay. The purpose of this study was to develop a simple indirect 3ABC ELISA using complete 3ABC protein. The full-length mutated 3ABC protein with inactive 3Cpro (mu3ABC) gene was constructed. The histidine-tagged mu3ABC protein was produced in insect cells for easy purification and measuring. This permits simple assay design and reproducible assay development. mu3ABC ELISA had diagnostic specificity and sensitivity of 96.6% and 84%, respectively, compared to Ceditest® FMDV-NS. Agreement of both assays was excellent with κ value of 0.823 (p <0.05). The mu3ABC ELISA could distinguish infected from vaccinated animals. These factors are necessary for the successful development of an in-house NSP-based ELISA. Availability of a reliable assay with acceptable costs would facilitate successful disease control and the establishment of disease-free zones. Expansion of such zones may ultimately decrease the risk of introducing FMDV into disease-free countries, thus accelerating global FMD control. [Copyright &y& Elsevier]